Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

The Phase III ASPECT Trial (Apadenoson Single Photo Emission Computed Tomography) is a randomized, double blind, active control study designed to determine whether Stedivaze is as effective as adenosine when used as a pharmacologic stress agent in SPECT MPI studies. Approximately 750 patients will be enrolled over an 18 to 24 month period at investigative sites in the U.S. Patients in the study will first undergo a clinically indicated SPECT MPI and then be randomized to receive a second SPECT MPI using either adenosine or Stedivaze. The incidence and severity of commonly reported side effects, such as shortness of breath, chest pain, dizziness, and headache, will also be evaluated to determine whether Stedivaze exhibits improved tolerability compared to adenosine.

About Stedivaze

Stedivaze (apadenoson) is a potent agonist of the adenosine A2A receptor subtype and offers improved selectivity over other adenosine receptor subtypes (A1 and A2B). Phase II studies suggest that Stedivaze produces ample coronary vasodilatory activity needed for cardiac stress MPI and has a pharmacokinetic profile that will allow it to be administered as a fixed dose bolus injection. Because of its improved selectivity for the A2A receptor subtype and its optimal pharmacokinetic profile, Stedivaze may offer improved tolerability over other adenosine receptor agonists currently marketed for use in pharmacologic stress MPI. Stedivaze is in Phase III clinical development for use as a pharmacologic agent for myocardial perfusion imaging with the goals of demonstrating equal efficacy and improved tolerability compared to adenosine.

About Myocardial Perfusion Imaging

Myocardial perfusion imaging is used as a primary screen to identify the presence of coronary artery disease (CAD) as evidenced by detection of areas of poor blood flow in the heart that can be caused by the formation of plaques that block the normal flow of blood to the heart. A pharmacologic stress agent is used to increase blood flow through coronary arteries temporarily during stress testing in order to more strikingly define areas of the heart that receive poor blood flow. The A2A adenosine receptor is the receptor subtype responsible for coronary vasodilation, or the widening of blood vessels.(1)

The U.S market for MPI testing is projected to be $800 million. Over 7.6 million MPI tests were performed in the United States in 2008 and approximately 3.5 million of these tests required the use of a pharmacological agent to generate maximum coronary blood flow in lieu of exercise.(2) The market is expected to continue to grow due to an increasing aging population, a rise in the number of patients unable to perform exercise during diagnostic procedures, and emerging imaging modalities that require the use of a vasodilator.

About Clinical Data, Inc.

Clinical Data develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in other major therapeutic areas. Clinical Data is also combining its drug development and biomarker expertise to develop products with enhanced efficacy and tolerability to improve patient health and reduce costs. To learn more, please visit the Company's website at www.clda.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and all other statements regarding future performance. All such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, risks related to whether Stedivaze or any of our therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration and equivalent foreign regulatory agencies and for which indications; whether Stedivaze or any of our other therapeutic products will be successfully marketed if approved; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2009, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009, and Current Reports on Form 8-K filed from time to time by the Company.

(1)Shryock, J.C., Snowdy, S., Baraldi, P.G., et al., "A2A -- adenosine Receptor Reserve for Coronary Vasodilation," Circulation, 1998, pp. 711-718.

(2)AMR Monthly Monitor SNM: Advanced Molecular Imaging and Therapy, September 15, 2008.

SOURCE: Clinical Data, Inc.

Clinical Data, Inc. 
Theresa McNeely, 617-527-9933, x3373 
Vice President 
Corporate Communications

The SAB members were chosen for their extensive investigations into the causes of inherited heart diseases, including cardiac channelopathies and cardiomyopathies, and their clinical expertise in treating these diseases. The members of PGxHealth's Scientific Advisory Board are:

-- Michael Ackerman, M.D., Ph.D., Pediatric Cardiologist at the Mayo Clinic and Director of Mayo's Long QT Syndrome Clinic, as well as Director of the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory;

-- Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Tufts Medical Center;

-- Silvia Priori, M.D., Ph.D, Professor of Medicine Director of Cardiovascular Genetics, Langone Medical Center, New York University, Associate Professor of Cardiology, Director of Molecular Cardiology, Fondazione Maugeri University of Pavia, Italy;

-- Jeffrey Towbin, M.D., Director of Cardiology and Co-director of Heart Institute at Cincinnati Children's Hospital, and

-- Arthur Wilde, M.D., Ph.D., Academic Medical Center, Amsterdam, The Netherlands.

In addition to attracting leading experts to its SAB, PGxHealth's leadership in cardiovascular genetic testing has been underscored by recent events, presentations and publications including:

-- Launch of the sixth FAMILION test, the FAMILION DCM Test for Dilated Cardiomyopathy, an inherited disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

-- Oral presentation at AHA 2009, "Evidence that Rare Missense Variants Seen in Long QT Syndrome-susceptibility Genes in Healthy Volunteers are not Pathogenic," presented in association with Mayo Clinic collaborators.

-- Publication in the current issue of the journal Circulation, "Genetic Testing for Long QT Syndrome -- Distinguishing Pathogenic Mutations from Benign Variants." Results of a multi-center study of Long QT Syndrome, a potentially lethal and highly treatable disorder involving the heart's electrical system, demonstrate that mutation type and location are critical determinants for distinguishing background noise from true LQTS-causative mutations.

-- Publication in the Heart Rhythm journal, "An International Compendium of Mutations in the SCN5A-Encoded Cardiac Sodium Channel in Patients Referred for Brugada Syndrome Genetic Testing." A retrospective analysis of Brugada Syndrome (BrS), a common heritable channelopathy, involving an international consortium of databases from 9 genetic testing centers, adds 200 new BrS-associated mutations to the public domain. http://www.heartrhythmjournal.com/article/S1547-5271(09)01142-4/abstract.

PGxHealth is committed to providing patients with access to the FAMILION family of genetic tests and has successfully contracted with major insurance companies, accepts Medicare assignment and is an approved Medicaid provider in certain states. The FAMILION LQTS Test now has coverage policies and agreements that cover over 250 million patients, representing an increase of over 50 million patients in 2009. In-network coverage by private payers also continues to increase, resulting in lower out-of-pocket costs for patients.

For more information about the FAMILION tests, please contact PGxHealth Customer Service at 877-2-PGxHealth (877-274-9432) or visit www.pgxhealth.com.

About PGxHealth(R)

PGxHealth, a division of Clinical Data, Inc., is utilizing its biomarker expertise and intellectual property to develop and commercialize targeted therapeutics as well as genetic and pharmacogenomic tests that detect serious diseases and help to predict drug safety and efficacy. By using innovative technologies and working with some of the world's most prestigious genomics thought leaders and institutions, PGxHealth is focused on improving clinical outcomes and reducing treatment costs in disease states and therapeutic classes with expensive, inefficient or suboptimal treatment options. Its tests are marketed under the FAMILION(R) and PGxPredict(R) brands. For more information, please visit PGxHealth's website at www.pgxhealth.com.

About Clinical Data, Inc.

Clinical Data develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in other major therapeutic areas. Clinical Data is also combing its drug development and biomarker expertise to develop products with enhanced efficacy and tolerability to improve patient health and reduce costs. To learn more, please visit the Company's website at www.clda.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to obtain regulatory approval for, and successfully introduce our therapeutic and biomarker products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our PGxPredict(R) tests, including but not limited to FAMILION(R), will gain wide acceptance in the market; the extent to which genetic markers are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2009, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009, and Current Reports on Form 8-K filed from time to time by the Company.

SOURCE: Clinical Data, Inc.

Clinical Data, Inc. 
Theresa McNeely, 617-527-9933 x3373 
Vice President 
Corporate Communications

In 2009, practice guidelines published by the Heart Failure Society of America (HFSA) supported the utilization of genetic testing for patients and their family members suspected of carrying mutations causative of DCM.(1) The FAMILION DCM Test is a complex genetic test that sequences the twelve genes most commonly associated with DCM. In addition, the FAMILION DCM Test is the only DCM panel to include SCN5A and ANKRD1, two genes known to account for 5% of gene mutations in familial DCM patients.(2,3,4)

"Starting with our proprietary FAMILION Long QT Syndrome Test, we have continued to leverage our unique expertise in cardiovascular genetics to provide a comprehensive portfolio of tests for inherited cardiac conditions," said Carol R. Reed, M.D., Chief Medical Officer of Clinical Data. "We remain committed to educating healthcare professionals, payors and patients about the role of genetics in helping to diagnose and better manage these potentially fatal diseases."

PGxHealth is committed to providing patients with access to the FAMILION family of genetic tests and has successfully contracted with major insurance companies, accepts Medicare assignment and is an approved Medicaid provider in certain states. The FAMILION LQTS Test now has coverage policies and agreements that cover over 250 million patients, an increase of over 50 million patients in 2009. In-network coverage by private payers also continues to increase, resulting in lower out-of-pocket costs for patients.

About DCM

Familial DCM is an inherited progressive heart disease most commonly presenting in the third or fourth decade of life. Symptoms associated with DCM include syncope (fainting), heart palpitations, dizziness and breathlessness. While there is no cure for DCM, there are treatments that can slow the progression of disease. Treatment options for confirmed DCM can include medication, and/or placement of a pacemaker or implantable cardiac defibrillator.

The FAMILION DCM Test will help clinicians diagnose familial DCM, interpret borderline clinical findings, and identify at-risk family members creating the opportunity for early intervention.

The FAMILION DCM Test sequences 12 genes (LMNA, ANKRD1, TNNC1, SCN5A, TPM1, MYBPC3, ACT1, LDB3, PLN, MYH7, TNNT2, TNNI3) and is performed in a CLIA-certified commercial laboratory that meets all applicable state and federal guidelines.

For more information about the FAMILION tests, please contact PGxHealth Customer Service at 877-2-PGxHealth (877-274-9432) or visit www.pgxhealth.com.

About PGxHealth(R)

PGxHealth, a division of Clinical Data, Inc., is utilizing its biomarker expertise and intellectual property to develop and commercialize targeted therapeutics as well as genetic and pharmacogenomic tests that detect serious diseases and help to predict drug safety and efficacy. By using innovative technologies and working with some of the world's most prestigious genomics thought leaders and institutions, PGxHealth is focused on improving clinical outcomes and reducing treatment costs in disease states and therapeutic classes with expensive, inefficient or suboptimal treatment options. Its tests are marketed under the FAMILION(R) and PGxPredict(R) brands. For more information, please visit PGxHealth's website at www.pgxhealth.com.

About Clinical Data, Inc.

Clinical Data develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in other major therapeutic areas. Clinical Data is also combing its drug development and biomarker expertise to develop products with enhanced efficacy and tolerability to improve patient health and reduce costs. To learn more, please visit the Company's website at www.clda.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to obtain regulatory approval for, and successfully introduce our therapeutic and biomarker products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our PGxPredict(R) tests, including but not limited to FAMILION(R), will gain wide acceptance in the market; the extent to which genetic markers are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2009, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009, and Current Reports on Form 8-K filed from time to time by the Company.

(1)Hershberger RE, Lindenfeld J, et al. Genetic evaluation of cardiomyopathy -- a heart failure society of America practice guideline. Journal of Cardiac Failure. 2009;15:83-9.

(2)Duboscq-Bidot L, Charron P, Ruppert V, et al. Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. Eur Heart J. 2009;30:2128-36.

(3)Moulik M, Vatta M, Witt SH, et al. ANKRD1, the gene encoding cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene. J Am Coll Cardiol. 2009 54:325-33.

(4)Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005;293:447-54.

SOURCE: Clinical Data, Inc.

Clinical Data, Inc. 
Theresa McNeely, 617-527-9933 x3373 
Vice President 
Corporate Communications